Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.60 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | HRH1 | P35367 | 2/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | CHIT1 | Q13231 | 3/20 | 0.46 |
| ▸ | CHIA | Q9BZP6 | 3/20 | 0.46 |
| ▸ | CHI3L1 | P36222 | 1/20 | 0.46 |
| ▸ | CHI3L2 | Q15782 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1967611 | 0.83 | CHIA (0.54) | TAAR1SIGMAR1CHIT1CHIACHI3L1 | |
| SCHEMBL1968987 | 0.83 | CHIA (0.54) | TAAR1SIGMAR1CHIT1CHIACHI3L1 | |
| SCHEMBL1966648 | 0.82 | TAAR1 (0.47) | TAAR1CHIT1CHIACHI3L1CHI3L2 | |
| SCHEMBL1242233 | 0.81 | TAAR1 (0.60) | TAAR1SIGMAR1CHIT1CHIACHI3L1 | |
| SCHEMBL27817743 | 0.81 | HTR2A (0.49) | CHIT1CHIACHI3L1CHI3L2GRIN2B | |
| SCHEMBL27817745 | 0.81 | CHIT1 (0.63) | TAAR1AOC3SIGMAR1CHIT1CHIA | |
| SCHEMBL1967143 | 0.81 | GRIN2B (0.63) | TAAR1AOC3SIGMAR1CHIAGRIN2B | |
| SCHEMBL13452623 | 0.81 | HRH3 (0.59) | TAAR1AOC3CYP2D6HRH1CHRM1 | |
| SCHEMBL23580210 | 0.79 | TACR1 (0.54) | TAAR1AOC3GRIN2B | |
| SCHEMBL12891009 | 0.79 | CHIT1 (0.57) | SIGMAR1CHIT1CHIACHI3L1CHI3L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| CN-102164896-A | Phenethylamide derivatives and their heterocyclic analogues | ACTELION PHARMACEUTICALS LTD | 2011-08-24 | — | — | CN | disclosed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010044054-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | TAAR1 48/4885AOC3 550/4885CYP2D6 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.